# AngioScore

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angioscore

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.angioscore.com
- Total disclosed funding: $88M
- Latest round: Series F (Apr 20, 2011)
- Investors on record: 8

## About

AngioScore, Inc. specializes in innovative solutions for cardiovascular health, focusing on advanced medical devices that improve patient care through precise lead extraction and vascular interventions.AngioScore, Inc. was founded in 2003 and is headquartered in Fremont, US. The company develops medical technologies aimed at enhancing cardiac and vascular care. In May 2014, Spectranetics Corporation acquired AngioScore for USD 230.000 mn. The company has engaged in 9 deals to date, reflecting its strategic alignment within the cardiovascular device market.AngioScore’s products focus on lead management devices and extraction sheaths, essential for managing cardiac implantable electronic device (CIED) infections. Their offerings also include solutions for vascular care procedures, utilized by healthcare providers in North America, Europe, and select Asian markets, aimed at treating various vascular conditions and improving patient outcomes.AngioScore generates revenue through direct sales of its medical devices to healthcare institutions, specifically hospitals and specialized clinics. The pricing of their products varies based on device complexity, with a strong emphasis on quality and reliability in meeting healthcare demands. Their lead extraction systems and vascular intervention tools represent key revenue-generating product lines.Following its acquisition by Spectranetics Corporation, AngioScore is positioned for growth through the development of new products and solutions tailored for cardiovascular care. The strategic acquisition will leverage Spectranetics’ resources to enhance product offerings and expand into new geographic markets, including Europe and Asia, by 2025. The recent funding of USD 230.000 mn from the acquisition will support these initiatives, facilitating research and product development aimed at improving healthcare outcomes.

## Funding rounds

- Series F, Apr 20, 2011, $12M — Jerusalem Venture Partners, Psilos Group, Telegraph Hill Partners, Pelion Venture Partners, Questmark Management Company, Saints Capital, California Technology Ventures
- Series E, Oct 9, 2007, $31M — Jerusalem Venture Partners, Psilos Group, Telegraph Hill Partners, Pelion Venture Partners, Questmark Management Company, California Technology Ventures
- Series D, Apr 11, 2006, $30M — Psilos Group, Telegraph Hill Partners, Pelion Venture Partners, Questmark Management Company, California Technology Ventures, Jerusalem Global Ventures
- Series B, Aug 23, 2004, $15M — Psilos Group, Pelion Venture Partners, California Technology Ventures, Jerusalem Global Ventures

## Investors

- Psilos Group (https://capitalatlas.ai/funds/psilos-group) — Series B, Series D, Series E, Series F
- Pelion Venture Partners (https://capitalatlas.ai/funds/pelion-venture-partners) — Series B, Series D, Series E, Series F
- California Technology Ventures (https://capitalatlas.ai/funds/california-technology-ventures) — Series B, Series D, Series E, Series F
- Jerusalem Global Ventures (https://capitalatlas.ai/funds/jerusalem-global-ventures) — Series B, Series D
- Telegraph Hill Partners (https://capitalatlas.ai/funds/telegraph-hill-partners) — Series D, Series E, Series F
- Questmark Management Company (https://capitalatlas.ai/funds/questmark-management-company) — Series D, Series E, Series F
- Jerusalem Venture Partners (https://capitalatlas.ai/funds/jerusalem-venture-partners) — Series E, Series F
- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series F